BioAt­la rakes in $72.5M Se­ries D, ad­vanc­ing re­search for pH-de­tect­ing can­cer treat­ments

A lit­tle over a year af­ter agree­ing to a world­wide col­lab­o­ra­tion with hefty Chi­nese biotech BeiGene worth up to $270 mil­lion, BioAt­la is ready for an­oth­er haul.

The San Diego-based biotech pulled in a $72.5 mil­lion haul for their Se­ries D fi­nanc­ing, which the com­pa­ny an­nounced Wednes­day. Funds will go to­ward their four main clin­i­cal pro­grams de­vel­op­ing can­cer treat­ments, two of which are cur­rent­ly in Phase II, BioAt­la pres­i­dent and for­mer Cel­gene COO Scott Smith said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.